1. Show article details.

    BULLET: US PIPELINE: Further to bullet at 07:31ET -- Avago...

    Market News Intl Fixed Income Bullets – 7:33 AM ET 05/28/2015

    US PIPELINE: Further to bullet at 07:31ET -- Avago Tech's (AVGO) potential near-term debt transaction will add more fuel to an already swollen pipeline filled with potential new M&A financing. Among the long list of recent corporate actions, Danaher Corp. (DHR) could well announce a new investment-grade debt sale in the near-term after the company recently agreed to acquire Pall Corp. (PLL) for an estimated $13.8 billion, including assumed debt. Also, Teva Pharmaceutical Industries Ltd. may announce a new debt sale in the near-term to help finance its recently proposed $43 billion acquisition of Mylan N.V.

  2. Show article details.

    Teva Reports Small Stake in Mylan

    DJ Business News – 5:55 PM ET 05/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA), which is seeking to buy rival Mylan NV (MYL), disclosed a small stake in the generic-drug maker. Teva said its purchase of a 1.35% Mylan interest underscores its commitment to a deal. The company is pursuing Mylan with a $40 billion unsolicited cash-and-stock offer, and Mylan is simultaneously chasing a reluctant Perrigo Co. (PRGO) with a $36 billion cash-and-stock bid.

  3. Show article details.

    Teva Reports Small Stake in Mylan

    DJ Business News – 5:44 PM ET 05/27/2015

    Teva Pharmaceutical Industries Ltd. (TEVA), which is seeking to buy rival Mylan NV (MYL), disclosed a small stake in the generic-drug maker. Teva said its purchase of a 1.35% Mylan interest underscores its commitment to a deal. The company is pursuing Mylan with a $40 billion unsolicited cash-and-stock offer, and Mylan is simultaneously chasing a reluctant Perrigo Co. with a $36 billion cash-and-stock bid.

  4. Show article details.

    Teva discloses 1.35 pct stake in target Mylan

    Reuters – 4:42 PM ET 05/27/2015

    Teva Pharmaceutical Industries Ltd (TEVA) disclosed a 1.35 percent interest in Mylan NV (MYL), saying the purchase underscored its commitment to buy Mylan as soon as possible. The company said it was ready to meet with Mylan and its advisers to discuss the deal. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month.

  5. Show article details.

    Mylan to Present at the Bernstein Strategic Decisions Conference

    PR Newswire – 4:48 PM ET 05/26/2015

    HERTFORDSHIRE, England and PITTSBURGH, May 26, 2015 Mylan N.V. (MYL), a leading global pharmaceutical company, today announced that Mylan CEO Heather Bresch, will be presenting at the Bernstein Strategic Decisions Conference, Friday, May 29, 2015 at 9 a.m. ET.

  6. Show article details.

    Mylan/Perrigo Clarification

    PR Newswire – 9:47 AM ET 05/25/2015

    HERTSFORDSHIRE, England, May 25, 2015 Mylan N.V. (MYL) today announced that it was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish Takeover Rules, relating to its firm intention to make an offer to acquire the issued and to be issued shares of Perrigo. The clarification and retraction relates to certain forward-looking statements made...

  7. Show article details.

    Law Firm Advising Teva Dismisses Mylan Objections

    DJ Business News – 4:45 PM ET 05/21/2015

    Kirkland& Ellis LLP punched back at Mylan NV' s attempt to disqualify the law firm from advising Teva Pharmaceutical Industries Ltd. (TEVA) in its bid for Mylan, dismissing the effort as an antitakeover tactic. Kirkland said its limited regulatory and litigation work for Mylan shouldn' t prevent it from advising Teva on a $40 billion offer, which Mylan has rejected. Mylan, based in the Netherlands, sued earlier this month to disqualify Kirkland from the matter.

  8. Show article details.

    Law Firm Advising Teva on Bid Dismisses Mylan's Objections to Its Involvement

    DJ Business News – 4:39 PM ET 05/21/2015

    Kirkland& Ellis LLP punched back at Mylan NV's (MYL) attempt to disqualify the law firm from advising Teva Pharmaceutical Industries Ltd. (TEVA) in its bid for Mylan, dismissing the effort as an antitakeover tactic. Kirkland said its limited regulatory and litigation work for Mylan shouldn't prevent it from advising Teva on a $40 billion offer, which Mylan has rejected. Mylan, based in the Netherlands, sued earlier this month to disqualify Kirkland from the matter.

  9. Show article details.

    BULLET: US PIPELINE: The trend of raising funds to help......

    Market News Intl Fixed Income Bullets – 4:07 PM ET 05/14/2015

    US PIPELINE: The trend of raising funds to help finance M&A, as well as to repurchase shares and increase dividends is likely to continue as rates remain low. The near-term pipeline could well include a new investment-grade debt sale from Danaher Corp. (DHR) after the company Wed announced it will acquire Pall Corp. (PLL) for an estimated $13.8 billion, including assumed debt. Danaher (DHR) said it expects to finance the transaction primarily with available cash and proceeds from the issuance of debt or new credit facilities. Also, Teva Pharmaceutical Industries (TEVA) may announce a new debt sale in the near-term to help finance its recently proposed $43 billion acquisition of Mylan NV (MYL). Visit the US$ Credit Supply Pipeline for a full list of deals.

  10. Show article details.

    Mylan to Present at the UBS Global Healthcare Conference

    PR Newswire – 4:00 PM ET 05/12/2015

    HERTSFORDSHIRE, England and PITTSBURGH, May 12, 2015 Mylan N.V. (MYL) today announced that the Company will present at the UBS Global Healthcare Conference on Monday May 18, 2015. The presentation is scheduled to begin at 9:30 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors.

  11. Show article details.

    Perrigo to Buy Patheon's Mexican Business

    DJ Business News – 10:05 AM ET 05/12/2015

    Perrigo Co. (PRGO), in the midst of a three-way takeover tussle, said Tuesday that it has agreed to buy the Mexican operations of Patheon for $34 million in cash. Perrigo Chief Executive Joseph C. Papa said the deal will give Perrigo (PRGO) manufacturing technology for softgel products-- long a desire for the company. Durham, N.C.-based Patheon is a unit of privately-held DPx Holdings B.V.

  12. Show article details.

    Perrigo to Buy Patheon's Mexican Business for $34 Million

    DJ Business News – 9:40 AM ET 05/12/2015

    Perrigo Co. (PRGO), in the midst of a three-way takeover tussle, said Tuesday that it has agreed to buy the Mexican operations of Patheon for $34 million in cash. Perrigo Chief Executive Joseph C. Papa said the deal will give Perrigo (PRGO) manufacturing technology for softgel products--long a desire for the company. Durham, N.C.-based Patheon is a unit of privately-held DPx Holdings B.V.

  13. Show article details.

    Mylan to Present at the Bank of America Merrill Lynch Health Care Conference

    PR Newswire – 7:30 AM ET 05/12/2015

    HERTSFORDSHIRE, England and PITTSBURGH, May 12, 2015 Mylan N.V. (MYL) today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 13, 2015. The presentation is scheduled to begin at 6:00 p.m. ET.

  14. Show article details.

    Mylan chairman said to consider Perrigo sweeteners to make deal -Bloomberg

    Reuters – 9:47 PM ET 05/11/2015

    Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc (PRGO) by adding terms that will reduce risk to Perrigo's (PRGO) shareholders, sources told Bloomberg on Monday.

  15. Show article details.

    BRIEF-Stada targets forex-adj Russia sales growth of 17-20 pct

    Reuters – 6:37 AM ET 05/07/2015

    Stada CEO in conference call. * Says expects Russia business to bottom out in Q4 at the latest. * Says Teva-Mylan merger could create antitrust-related asset sales that we will look into. * Says targeting Russia sales growth of 17-20 percent in 2015 when adjusted for currency effects Further company coverage:

  16. Show article details.

    Fashion Icon, Chef and Actor Join Together to Share Personal Stories of Managing Life-Threatening Allergies in New Campaign

    PR Newswire – 6:30 AM ET 05/07/2015

    POTTERS BAR, ENGLAND, AND PITTSBURGH, May 7, 2015 Mylan N.V., a leading global pharmaceutical company, today announced the launch of EpiPen® On Location™. This campaign is a national call-to-action to help those living with potentially life-threatening allergies and their caregivers understand the importance of being prepared for a life-threatening allergic reaction by avoiding allergic tri...

  17. Show article details.

    BRIEF-Mylan confident it can close Perrigo deal by year end

    Reuters – 5:51 PM ET 05/05/2015

    Mylan Sees q2 adjusted eps $0.86 to $0.90. * Mylan says Perrigo (PRGO) acquisition would create $800 million in synergies by year 4 after closing. * Says Mylan and Perrigo (PRGO) are highly complementary businesses. * Mylan says confident it can close Perrigo (PRGO) deal by year end Further company coverage:

  18. Show article details.

    Mylan's Revenue Misses on Currency Effects

    DJ Business News – 5:05 PM ET 05/05/2015

    Mylan NV (MYL) on Tuesday said revenue rose a less-than-expected 9%, as foreign currency and acquisition costs weighed on results. Shares, up 29% this year through Tuesday's close, fell less than 1% in after-market trading. The company affirmed its full-year outlook.

  19. Show article details.

    Mylan says can close Perrigo deal by year end, reports profit

    Reuters – 4:46 PM ET 05/05/2015

    Generic drugmaker Mylan NV (MYL), at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland-based Perrigo Co (PRGO) and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo (PRGO) shareholders under Irish takeover rules.

  20. Show article details.

    Mylan reports profit, maintains commitment to acquire Perrigo

    Reuters – 4:25 PM ET 05/05/2015

    Generic drugmaker Mylan NV (MYL), at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland-based Perrigo Co. Excluding items, such as acquisition costs for a deal with Abbott Laboratories that enabled it to redomicile in Europe, Mylan earned 70 cents per share.

Page:

Today's and Upcoming Events

  • Aug
    6

    MYL to announce Q2 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.